Compare GSK plc (GSK) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Mattel Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Mattel Inc trades at $16.69 (market cap $4.74B). The key difference: GSK plc is far larger — about 19.4× Mattel Inc's market cap, and GSK plc pays a 3.9% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Mattel Inc for 97 Days on average.
| GSK | MAT | |
|---|---|---|
Market Cap | $91.88B | $4.74B |
Volume | 7,730,529 | 11,809,722 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $22.16 |
52-Week Low | $43.24 | $12.66 |
Typical Hold Time | 93 Days | 97 Days |
Enterprise Value | $111.88B | $6.96B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Mattel (MAT) trades at $16.58, up 1.28% with strong technical momentum and bullish analyst sentiment. Recent takeover interest from Authentic Brands Group has boosted the stock, while CEO transition to Roger Lynch marks a leadership shift. The company maintains solid fundamentals with $5.35B revenue, 7.78% net margin, and attractive valuation at P/E 12.38. Technical indicators show bullish momentum despite overbought RSI readings.
Mattel presents a compelling opportunity with takeover speculation and reasonable valuation, though execution risks under new leadership and mixed earnings performance warrant caution. The stock's current momentum appears driven by M&A speculation rather than fundamental improvement, creating potential volatility. Wall Street maintains a bullish stance with 53% buy ratings and $15 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
